Italia markets open in 6 hours 2 minutes

OpGen, Inc. (OPGN)

NasdaqCM - NasdaqCM Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,5300-0,0100 (-0,39%)
Alla chiusura: 04:00PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,5400
Aperto2,5600
Denaro0,0000 x 0
Domanda0,0000 x 0
Min-Max giorno2,4933 - 2,6200
Intervallo di 52 settimane1,6500 - 38,4000
Volume9.206
Media Volume43.230
Capitalizzazione3,453M
Beta (mensile su 5 anni)-0,65
Rapporto PE (ttm)N/D
EPS (ttm)-41,4700
Prossima data utili27 giu 2024 - 05 lug 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds

    ROCKVILLE, Md., Oct. 12, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the Company for cash (the “Existing Warrants”), wherein the investor agreed to exercise the Existing Warrants to pur

  • GlobeNewswire

    OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “

  • GlobeNewswire

    OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

    Single nucleotide polymorphism (SNP) analysis module and interpretation of plasmids now availableAdded reporting customized for the needs of hospital epidemiologists Signed first large commercial contract with U.S. healthcare network using the new features ROCKVILLE, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Gen